NV-ROBOSENSE
8.1.2020 15:02:09 CET | Business Wire | Press release
RoboSense (http://www.robosense.ai ), the leading autonomous driving LiDAR perception solution provider, announced today the world’s first public road test of a vehicle equipped with a Smart LiDAR Sensor at CES 2020 . The RoboSense Smart LiDAR car, featuring the award-winning RS-LiDAR-M1 Smart LiDAR , will be running outside the Las Vegas Convention Center daily during CES 2020, showing the latest technological progress in autonomous vehicle LiDAR. Simultaneous exhibitions will be held at RoboSense’s CES Booth #6138 at the LVCC, North Hall showcasing the real-time 3D point cloud data on a vehicle equipped with the multi solid state LiDAR fusion system.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200108005303/en/
First MEMS Smart LiDAR Sensor to Incorporate Sensor Hardware, AI Perception Algorithms, & IC Chipsets
The RoboSense RS-LiDAR-M1 Smart LiDAR is the world’s first MEMS Smart LiDAR Sensor to incorporate sensor hardware, AI perception algorithms, and IC chipsets, transforming conventional LiDAR sensors from an information collector to a complete data analysis and comprehension system, providing essential information for autonomous vehicle decision-making faster than ever before. The RS-LiDAR-M1 is the winner of the CES Innovation Award for two consecutive years in a row, 2019 and 2020.
RoboSense Co-Partner and Vice President of R&D, Dr. Leilei Shinohara, said, “After optimization based on large amounts of data, RoboSense’s algorithm performance and software stability and reliability have proven to have many key advantages. Developed by RoboSense after more than a decade of exhaustive research in perception technology, it has combined the advantages of deep-learning-based AI algorithm with the traditional algorithms to keep functional safety. Since 2017, RoboSense’s algorithms have gained more than 100 global partners for various types of autonomous driving scenario certifications.”
At CES and on the streets of Las Vegas, the RoboSense RS-LiDAR-M1 Smart is demonstrating that it is the world’s first and only Smart LiDAR capable of real road tests on open roads .
128 Laser Beam System & Fastest Mass-produced Short-range LiDAR for Blind Spot Detection
During CES 2020, RoboSense128-beams LiDAR RS-Ruby and the short-range Blind Spot LiDAR RS-BPearl also go on public road demo, meanwhile there is also a simultaneous exhibition at RoboSense Booth. This super high-performance 128-beam LiDAR RS-Ruby possesses an ultra-high resolution of 0.1° and the range performance of 200m for a 10% reflectivity target.
The RS-BPearl, the first mass-produced short-range LiDAR for blind-spot detection, reaches the minimum detection range of less than several centimeters, with hemispheric FOV coverage of 90° * 360°, which not only precisely identifies objects around the vehicle’s body, but can also detect the actual height information in particular scenarios, such as with bridge tunnels and culverts.
RoboSense Partner Demonstrations at CES 2020
RoboSense has partnerships with numerous industry leaders who will be announcing partnerships or co-demonstrating with RoboSense at CES, including ON Semiconductor, Xilinx, Horizon, AutoX, and Freetech.
Wade Appelman, Vice President of ISG, SensL Division, ON Semiconductor, said, “The combo of RoboSense LiDAR with the ON Semiconductor RD Series SiPM family of products will perform much better than the older APD technology employed by legacy LiDAR manufacturers using mechanical scanning architectures, further enhancing the performance of the RS-LiDAR-M1 to be one of the best in the automotive LiDAR market.”
About RoboSense
The world’s leading autonomous driving LiDAR perception solution provider. http://www.robosense.ai .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200108005303/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom